Extract

This study is a Phase 2 randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group study designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple doses of ABT-122 in subjects with active psoriatic arthritis (PsA) who are inadequately responding to methotrexate (MTX) treatment.

Inclusion criteria

• Psoriatic Arthritis

Country

• Australia
• Bulgaria
• Czech Republic
• France
• Germany
• Hungary
• Italy
• Latvia
• New Zealand
• Poland
• Romania
• Spain
• United States

Links

• nct
• ictrp